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Abstract
Background: Impaired liver function in men can result in erectile dysfunction or hypogonadism or both. We
investigated whether living donor liver transplantation (LDLT) results in improvement in male sexual function.
Methods: A total of 58 patients with end-stage liver disease (ESLD) were included in this prospective, cross-sectional
study. Erectile function was measured before and after LDLT using a five-item modified version of the International
Index of Erectile Function scale (IIEF-5) and hypogonadism was evaluated before and after LDLT using the Androgen
Deficiency in the Aging Male (ADAM) questionnaire. Differences in mean values from the questionnaires before and
after the operation were than evaluated to determine whether there is an association between LDLT and improvement
in sexual function.
Results: We found that mean IIEF-5 scores significantly increased after LDLT (from 11.7 ± 7.7 before LDLT to 14.7 ± 7.5
after LDLT, p <0.01), indicating that the operation played a role in improving erectile function. In addition, the
prevalence of hypogonadism among the patients with ESLD decreased markedly after liver transplantation
(hypogonadism before LDLT, n = 41 versus hypogonadism after LDLT, n = 31, p = 0.03). Patients with hypogonadism
reported a higher prevalence of erectile dysfunction after LDLT than patients without hypogonadism (p <0.01).
Conclusions: LDLT results in improvement in erectile function. In addition, improvement in erectile function is
associated with self-reported absence of hypogonadism.
Background
Liver transplantation is considered standard curative
therapy for patients with advanced hepatocellular carcin-
oma and for patients with alcohol-related end-stage liver
disease (ESLD). Improvements in surgical techniques as
well as medical therapy have resulted in better long-term
survival outcomes for patients who require liver trans-
plantation. However, patients with chronic disease tend to
care more about quality of life than about the duration of
life. Sexual function, a component of quality of life, is a
major concern for men with ESLD and for those who
have received liver transplantation [1, 2]. Damage to
the hypothalamic-pituitary-gonadal axis and impaired
liver function are the main causes of sexual dysfunction
in patients with cirrhosis [1, 3]. Studies have shown that
orthotopic liver transplantation (OLT) can result in restor-
ation of the hypothalamic-pituitary-gonadal axis [4, 5].
Religious beliefs, cultural values, educational systems
and differences in legislation associated with brain death
help to explain why OLT is not as common in Asian
countries as in Western countries [6]. Increased need for
liver transplantation and a shortage of deceased donors
led to the development of living donor liver transplant-
ation (LDLT) as an alternative to OLT. Although long-
term survival rates, organ rejection rates, and rates of
hepatitis C virus (HCV) recurrence have been shown to
be more or less equal between LDLT and OLT, studies
have shown that LDLT is associated with a shorter is-
chemic time, a lower mortality rate, and greater peri-
operative benefits than OLT [7].
The prevalence of erectile dysfunction is high in pa-
tients with ESLD [8]. Although the gold standard for
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determining the presence of hypogonadism in men is
measuring free testosterone level, that test is not widely
performed in clinical laboratories. An alternative to meas-
uring free testosterone in serum is to administer the self-
report Androgen Deficiency in the Aging Male (ADAM)
questionnaire, which is designed to assess symptoms
associated with androgen deficiency and, therefore, can
be used as a tool to detect and measure the degree of
hypogonadism. The ADAM questionnaire is a simple, non-
invasive measure that has been shown to have a high
sensitivity and a relatively acceptable specificity [9, 10].
Erectile dysfunction (ED) is defined as the inability to
develop or maintain an erection during sexual intercourse
and is the main domain of sexual dysfunction in men [8].
Although ED is an important quality-of-life issue, it is
often underestimated by patients and physicians. The
five-item International Index of Erection Function (IIEF-5)
questionnaire provides a measurable scale with which to
estimate the true prevalence of ED [11]. To the best of our
knowledge, no studies have evaluated the effect of LDLT
on sexual function in men. Thus, in this study, we mea-
sured the differences in pre- and post-surgical IIEF-5 and
ADAM questionnaire scores to investigate whether LDLT
affects sexual function in men.
Methods
Patients
The patients in this prospective cohort study comprised
68 men with end-stage liver disease who were scheduled
to undergo LDLT at the Changhua Christian hospital
(Changhua, Taiwan) during the period 2006–2012. Written
informed consents were obtained from the patients. The
five-item International Index of Erection Function (IIEF-5)
questionnaire, designed to evaluate erectile dysfunction,
and the Androgen Deficiency in the Aging Male (ADAM)
questionnaire, designed to measure the degree of hypo-
gonadism, were administered to the patients before LDLT
and six months after the operation. Patients were required
to complete the IIEF-5 questionnaire in the outpatient de-
partment about six to seven months after transplantation.
At the end of the study period, 10 men were excluded
from the study because of because of working abroad
(n = 2), because they refused to complete the question-
naires (n = 6), or because of self-reported inability to
understand the questionnaire during the post-operative
period (n = 2). Therefore, data on 58 patients were eval-
uated (Fig. 1).
The Institutional Review Board of the Changhua Chris-
tian hospital approved the study.
Inclusion and exclusion criteria
Adult (≥18 years) male recipients of living donor liver
transplant who had completed a 6-month follow-up
assessment were considered eligible for inclusion. Ex-
clusion criteria included female gender, age < 18 years,
liver graft failure, refusal to complete the post-LDLT
questionnaires, and loss to follow-up for any reason.
Survey
An introductory letter comprising a detailed description
of the methodology of the study, the future consequences
of the study, the name of the contact person of the study,
and associated information was presented to each partici-
pant before LDLT. Data collection was completed by two
doctors in the urology division of the surgery department
via telephone or face-to-face interview. Etiology of liver
disease (hepatitis B virus, hepatitis C virus, or alcoholism),
Fig. 1 Scheme of patient selection in the study
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alcohol intake history, the presence of diabetes and demo-
graphic data were obtained through chart review.
Main outcome measures
Measures
The International Index of Erectile Function (IIEF), also
known as the Sexual Health Inventory for Men (SHIM),
is a widely used questionnaire for the evaluation of male
sexual function and is recommended as a primary end-
point for diagnostic evaluation of ED severity by the
National Institutes of Health Consensus Panel on Im-
potence [12]. The IIEF-5 is a modified version of the
IIEF comprising five items instead of 15 items and was
designed to shorten the time needed to complete the
survey. The IIEF-5 questionnaire shows the presence and
severity of ED over the past six months [13]. Studies have
shown that the validity and sensitivity of the IIEF-5 are
similar to those of the original IIEF scale [11, 14]. The
IIEF-5 is graded on a scale from 1 to 5 points for each
of the five items. The total score therefore ranges from
5 to 25. The primary score is classified into five cat-
egories of severity, namely severe (score 5–7), moderate
(score 8–11), mild-to-moderate (score 12–16), mild
(score 17–21), and no ED (score 22–25). The Androgen
Deficiency in the Aging Male (ADAM) questionnaire is
a self-report, ten-item scale designed to evaluate the
degree of androgen deficiency [10]. ADAM consists of
10 questions and answering “yes” to question 1 or 7 or
to 3 or more of the questions is regard as an indication
of possible hypogonadal status. ADAM has been shown
to be a highly sensitive but poorly specific measure for
determining androgen deficiency [15]. Nonetheless,
Tancredi et al. found that hormone analysis of blood
samples correlated with ADAM scores [9]. Patients who
reported decreased libido or inadequate erectile “strength”
and patients who provided positive answers to 3 of the
other questions listed in the questionnaire were con-
sidered to have androgen deficiency. Both questionnaires
were given to patients before LDLT and at least six
months after the operation to evaluate whether LDLT
had an effect on erectile dysfunction and hypogonadism.
Statistical analysis
Categorical data were compared by the McNemar's test
or the Chi-square test. Differences in continuous vari-
ables were compared by the Wilcoxon signed-rank test.
A p value of less than 0.05 was considered to indicate
statistical significance. All statistical analyses were per-
formed on a personal computer with the statistical pack-
age SPSS for Windows (Version 18.0, SPSS, Chicago, Il).
Results
During the period November 2012 to May 2013, 58 of
the 68 (85 %) adult men who were eligible to participate
in the study completed both questionnaires before and
after LDLT. Reasons for not completing the questionnaires
during the post-operative period included refusal to partici-
pate (n = 6), working abroad (n = 2), and self-reported in-
ability to understand the questionnaire (n = 2). Table 1
summarizes the general characteristics of the patients
who participated in the study. The mean age at the time
of LDLT was 53.86 ± 7.53 years. Alcohol abuse was self-
reported in 17 patients before LDLT and in 4 after the
operation. In addition, 15 of the patients had diabetes
mellitus before surgery and 27 had the disorder after
LDLT (Table 1).
Change in erectile dysfunction
We found that mean IIEF-5 scores significantly increased
after LDLT (from 11.7 ± 7.7 before LDLT to 14.7 ± 7.5
after LDLT, p <0.01), indicating that the operation played
a role in improving erectile function. Overall, 28 patients
reported improvement in erectile function, 23 patients
reported no change in erectile function and 7 patients
reported worse erectile function. We also found that
the degrees of ED changed among the study population
after surgery (Table 2). The percentage of patients with
IIEF-5 scores indicative of severe ED or mild-to-
moderate ED was markedly lower after LDLT (24.1 %
vs. 37.9 % and 17.2 % vs. 31.0 % respectively) and the
percentage of patients with IIEF-5 scores indicating no
ED was noticibly higher after LDLT (13.8 % vs. 6.9 %).
Interestingly, however, the percentage of patients with
scores indicative of moderate ED or mild ED was higher
Table 1 Characteristics of the population before and after transplantation
Before transplantationN (%) After transplantationN (%) p value
Age (years; mean ± SD) 53.86 ± 7.53 55.02 ± 7.33 < 0.001
Alcohol abuse 17 (29.3) 4 (6.9) < 0.001
HBV 34 (58.6) 1 (1.7) < 0.001
HCV 17 (29.3) 6 (10.3) 0.001
Diabetes 15 (25.9) 27 (46.6) < 0.001
IIEF5 score (mean ± SD) 11.7 ± 7.7 14.7 ± 7.5 0.001
Suspected hypogonadism via ADAM questionnaire 41 (70.6) 31 (53.4) 0.031
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after LDLT (5.2 % vs. 3.4 % and 39.7 % vs. 20.7 %, respect-
ively) (Table 2) (Fig. 2).
Change in hypogonadism
The prevalence of hypogonadism among the patients with
ESLD decreased markedly after liver transplantation based
on the scores from the ADAM questionnaires adminis-
tered before and after surgery (hypogonadism before LDLT,
n = 41 vs. hypogonadism after LDLT, n = 31, p = 0.031).
Association of erectile dysfunction and hypogonadism
We found that hypogonadism before LDLT was associ-
ated with improvement in erectile function after LDLT.
There was a significant correlation between hypogonad-
ism before LDLT and IIEF-5 score prior to LDLT (Fig. 3).
In patients with ADAM questionnaire scores indicating
no hypogonadism, the mean IIEF-5 score was 15.35 ±
6.89 prior to LDLT and 19.92 ± 4.92 after LDLT (p <0.01)
(Table 3). In patients with ADAM scores indicative of
hypogonadism, the mean IIEF-5 score was 8.75 ± 7.07 be-
fore surgery and 10.53 ± 6.65 after LDLT (p = 0.107).
Factors associated with post-LDLT erectile dysfunction
The existence of HCV infection was significantly associ-
ated with lower IIEF-5 scores (mean IIEF-5 score in pa-
tients with HCV = 11.06 ± 7.81 vs. mean IIEF-5 score in
patients without HCV = 16.27 ± 6.97, p = 0.015). Patients
with clinical evidence of DM had lower IIEF-5 scores than
those without diabetes (IIEF-5 of patients with DM=
12.15 ± 7.40 vs. IIEF-5 of patients without DM= 17.00 ±
7.02, p = 0.013). Other parameters such as alcohol-
related origin of liver disease, development of post-
transplantation DM, and gender of donor were not
associated with the development of post-LDLT erectile
dysfunction or hypogonadism.
Discussion
Determination of sexual health is challenging, especially
in Asian men who are often reluctant to undergo evalu-
ation of sexual function. The response rate among partici-
pants to questionnaires designed to survey sexual function
has been reported to range from 22.5 % to 81 % [8, 11, 16].
In our study, however, the response rate was 85 %. The
introductory letters written by the surgeon who performed
the LDLT procedures most likely contributed to the rela-
tively high compliance rate in our study. The etiology of
sexual dysfunction is multi-factorial and ESLD is one of
many factors associated with the disorder. Liver trans-
plantation restores liver function and should, theoretically,
result in improvements in sexual function [8]. However,
immunosuppressive drugs, which are key to survival after
liver transplantation, are known to impair sexual function
[17]. Alterations in the hypothalamic-pituitary-gonadal axis,
changes in estrogen-over-androgen ratio, and altered sex
hormone transport have been shown to cause hypogonad-
ism in patients with impaired liver function [16, 18, 19].
Decreased testosterone level, libido, testis size and even
infertility have been reported in patients with cirrhosis
[3, 20]. Foresta et al. reported decreased sex hormone
binding protein levels and higher free testosterone in
serum in patients after OLT, which may explain the
Table 2 Changes of erectile dysfunction prior to and after liver transplantation
Before transplantationN (%) After transplantationN (%) p value
Categories of IIEF5 score Severe ED 22 (37.9) 14 (24.1) < 0.001
Moderate ED 2 (3.4) 3 (5.2)
Mild to moderate ED 18 (31.0) 10 (17.2)
Mild ED 12 (20.7) 23 (39.7)
No ED 4 (6.9) 8 (13.8)
Fig. 2 Prevalence of erectile dysfunction prior to and after liver transplantation
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improvement in physiological function after the oper-
ation, even under immunosuppressive therapy [4]. Park
et al. reported that up to 60 % of men reported no im-
provement in erectile function after OLT [10]. Klein and
colleagues reported improvement in sexual function in-
cluding erectile function, sexual satisfaction and sexual de-
sire and a statistical trend in improvement in IIEF scores
after liver transplant [21]. In our study, we found that
nearly half of the patients reported improvement in erec-
tile function. Many factors contribute to ED, including
drugs, neurogenic disorders, cavernosal disorders, hor-
mones, psychological causes, surgery, aging, and diabetes
[22]. In our study, higher IIEF-5 scores were associated
with absence of hypogonadism after the operation. That
is, improvement in erectile function after liver transplant-
ation is mainly hormone related. Theoretically, irreversible
damage of the hypothalamic-pituitary-gonadal axis by
long-term consumption of alcohol implies the low possi-
bility of improvement in sexual function after LDLT [23].
However, Huyghe E et al. reported no higher risk of erec-
tile dysfunction in patients with end-stage liver disease
secondary to alcohol consumption [8]. Burra et al. also re-
ported that there was no significantly lower trend in IIEF
score in patients with alcohol-induced ESLD [3]. Sorrell
and Brown found that 40 % of patients developed erectile
dysfunction and 25 % reported having a lower level of
sexual satisfaction after liver transplantation [16]. Ho et al.
reported that 32 % of patients developed de novo sexual
dysfunction after OLT [24]. Cardiovascular disease, post-
transplantation diabetes, alcohol abuse, antidepressants
and angiotensin II receptor blockers have been shown
to be associated with new onset erectile dysfunction
after liver transplantation [8]. In our study, 12 % (n = 7)
of our patients reported a decrease in erectile function
Fig. 3 Correlation between erectile dysfunction before and after transplantation for patients with or without hypogonadism
Table 3 IIEF-5 scores before and after transplantation for each group
IIEF-5 score
Before transplantation(mean ± SD) After transplantation(mean ± SD) p value
With hypogonadism 8.75 ± 7.07 10.53 ± 6.65 0.109
Without hypogonadism 15.35 ± 6.89 19.92 ± 4.92 0.001
HCV positive 9.24 ± 6.98 11.06 ± 7.81 0.247
HCV negative 12.73 ± 7.80 16.27 ± 6.97 0.001
With DM 10.48 ± 6.51 12.15 ± 7.40 0.094
Without DM 12.77 ± 8.53 17.00 ± 7.02 0.002
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after LDLT. The low incidence of de novo erectile dys-
function might be due to the relatively short follow-up
period in our study.
There are several limitations in this study. First, im-
munosuppressive regimens after transplantation were not
consistent throughout the study population. Therefore, we
were not able to take pharmacologic factors into account.
Second, our findings are limited by the relatively small
sample size and short follow-up period. Third, we did not
measure serum testosterone levels and therefore we do
not have laboratory data to support the change in preva-
lence of hypogonadism. Nonetheless, to the best of our
knowledge, this is the first study to compare changes in
sexual function before and after LDLT. Large-scale studies
with longer follow-up periods are needed to clarify the
role liver transplantation plays in sexual function.
Conclusions
LDLT results in improvement in erectile function. In
addition, improvement in erectile function is associated
with absence of hypogonadism before LDLT.
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